172 related articles for article (PubMed ID: 23395884)
1. Overcoming resistance to rapalogs in gliomas by combinatory therapies.
Grzmil M; Hemmings BA
Biochim Biophys Acta; 2013 Jul; 1834(7):1371-80. PubMed ID: 23395884
[TBL] [Abstract][Full Text] [Related]
2. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Vicier C; Dieci MV; Andre F
Curr Opin Oncol; 2013 Nov; 25(6):587-93. PubMed ID: 24097108
[TBL] [Abstract][Full Text] [Related]
3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
4. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
[TBL] [Abstract][Full Text] [Related]
5. The Enigma of Rapamycin Dosage.
Mukhopadhyay S; Frias MA; Chatterjee A; Yellen P; Foster DA
Mol Cancer Ther; 2016 Mar; 15(3):347-53. PubMed ID: 26916116
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
Zhang YJ; Duan Y; Zheng XF
Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
[TBL] [Abstract][Full Text] [Related]
7. Drug discovery targeting the mTOR pathway.
Martelli AM; Buontempo F; McCubrey JA
Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
[TBL] [Abstract][Full Text] [Related]
8. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.
Gnant M
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1579-89. PubMed ID: 23253223
[TBL] [Abstract][Full Text] [Related]
9. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
10. Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models.
Rhein M; Schwarzer A; Yang M; Kaever V; Brugman M; Meyer J; Ganser A; Baum C; Li Z
Ann Hematol; 2011 Mar; 90(3):283-92. PubMed ID: 20821325
[TBL] [Abstract][Full Text] [Related]
11. Toward rapamycin analog (rapalog)-based precision cancer therapy.
Meng LH; Zheng XF
Acta Pharmacol Sin; 2015 Oct; 36(10):1163-9. PubMed ID: 26299952
[TBL] [Abstract][Full Text] [Related]
12. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of mTOR inhibitor resistance in cancer therapy.
Carew JS; Kelly KR; Nawrocki ST
Target Oncol; 2011 Mar; 6(1):17-27. PubMed ID: 21547705
[TBL] [Abstract][Full Text] [Related]
14. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
Khokhar NZ; Altman JK; Platanias LC
Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Huang Z; Wu Y; Zhou X; Qian J; Zhu W; Shu Y; Liu P
Future Oncol; 2015; 11(11):1687-99. PubMed ID: 26043220
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with mTOR inhibitors.
Pallet N; Legendre C
Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
[TBL] [Abstract][Full Text] [Related]
17. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
18. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
20. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
